-
1
-
-
34547193713
-
Guidelines on prostate cancer
-
Accessed: August 2011
-
A. Heidenreich, M. Bolla, S. Joniau Guidelines on prostate cancer Eur Assoc Urol 2011 2011 1 152 http://www.uroweb.org/gls/pdf/08-Prostate-Cancer.pdf Accessed: August 2011
-
(2011)
Eur Assoc Urol
, vol.2011
, pp. 1-152
-
-
Heidenreich, A.1
Bolla, M.2
Joniau, S.3
-
2
-
-
56649116179
-
The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
-
L. Klotz, L. Boccon-Gibod, N.D. Shore The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer BJU Int 102 2008 1531 1538
-
(2008)
BJU Int
, vol.102
, pp. 1531-1538
-
-
Klotz, L.1
Boccon-Gibod, L.2
Shore, N.D.3
-
3
-
-
0022367715
-
Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer
-
J. Waxman, A. Man, W.F. Hendry Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer Br Med J (Clin Res Ed) 291 1985 1387 1388 (Pubitemid 16212355)
-
(1985)
British Medical Journal
, vol.291
, Issue.6506
, pp. 1387-1388
-
-
Waxman, J.1
Man, A.2
Hendry, W.F.3
-
4
-
-
0025688334
-
Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate
-
I.M. Thompson, E.J. Zeidman, F.R. Rodriguez Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate J Urol 144 1990 1479 1480
-
(1990)
J Urol
, vol.144
, pp. 1479-1480
-
-
Thompson, I.M.1
Zeidman, E.J.2
Rodriguez, F.R.3
-
5
-
-
20344374658
-
Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: What is the optimal level of testosterone?
-
DOI 10.1016/j.eursup.2005.04.004, PII S1569905605000448, Prostate Cancer: Testosterone Suppression Levels and Eligard (R)
-
B. Tombal Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone? Eur Urol Suppl 4 2005 14 19 (Pubitemid 40780974)
-
(2005)
European Urology, Supplements
, vol.4
, Issue.5
, pp. 14-19
-
-
Tombal, B.1
-
6
-
-
43949144620
-
Management of advanced prostate cancer: Can we improve on androgen deprivation therapy?
-
DOI 10.1111/j.1464-410X.2008.07590.x
-
J. Anderson, P.A. Abrahamsson, D. Crawford Management of advanced prostate cancer: can we improve on androgen deprivation therapy? BJU Int 101 2008 1497 1501 (Pubitemid 351704035)
-
(2008)
BJU International
, vol.101
, Issue.12
, pp. 1497-1501
-
-
Anderson, J.1
Abrahamsson, P.-A.2
Crawford, D.3
Miller, K.4
Tombal, B.5
-
7
-
-
0029813882
-
Prospective study of sex hormone levels and risk of prostate cancer
-
P.H. Gann, C.H. Hennekens, J. Ma Prospective study of sex hormone levels and risk of prostate cancer Natl Cancer Inst 88 1996 1118 1126 (Pubitemid 26274606)
-
(1996)
Journal of the National Cancer Institute
, vol.88
, Issue.16
, pp. 1118-1126
-
-
Gann, P.H.1
Hennekens, C.H.2
Ma, J.3
Longcope, C.4
Stampfer, M.J.5
-
9
-
-
0034768230
-
Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer
-
T. Imamoto, H. Suzuki, K. Akakura Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer Endocr J 48 2001 573 578 (Pubitemid 33035347)
-
(2001)
Endocrine Journal
, vol.48
, Issue.5
, pp. 573-578
-
-
Imamoto, T.1
Suzuki, H.2
Akakura, K.3
Komiya, A.4
Nakamachi, H.5
Ichikawa, T.6
Igarashi, T.7
Ito, H.8
-
10
-
-
0030891205
-
Serum testosterone - A significant determinant of metastatic relapse for irradiated localized prostate cancer
-
DOI 10.1016/S0090-4295(96)00619-X, PII S009042959600619X
-
G.K. Zagars, A. Pollack, A.C. von Eschenbach Serum testosterone - a significant determinant of metastatic relapse for irradiated localized prostate cancer Urology 49 1997 327 334 (Pubitemid 27138671)
-
(1997)
Urology
, vol.49
, Issue.3
, pp. 327-334
-
-
Zagars, G.K.1
Pollack, A.2
Von Eschenbach, A.C.3
-
11
-
-
44049101301
-
The role of testosterone in the pathogenesis of prostate cancer
-
DOI 10.1111/j.1442-2042.2008.02074.x
-
T. Imamoto, H. Suzuki, M. Yano The role of testosterone in the pathogenesis of prostate cancer Int J Urol 15 2008 472 480 (Pubitemid 351713199)
-
(2008)
International Journal of Urology
, vol.15
, Issue.6
, pp. 472-480
-
-
Imamoto, T.1
Suzuki, H.2
Yano, M.3
Kawamura, K.4
Kamiya, N.5
Araki, K.6
Komiya, A.7
Nihei, N.8
Naya, Y.9
Ichikawa, T.10
-
12
-
-
39149084101
-
Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies
-
DOI 10.1093/jnci/djm323
-
A.W. Roddam, N.E. Allen Endogenous Hormones and Prostate Cancer Collaborative Group Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies J Natl Cancer Inst 100 3 2008 170 183 (Pubitemid 351480553)
-
(2008)
Journal of the National Cancer Institute
, vol.100
, Issue.3
, pp. 170-183
-
-
Roddam, A.W.1
Allen, N.E.2
Appleby, P.3
Key, T.J.4
-
13
-
-
53249121469
-
A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America
-
M. Gittelman, P.J. Pommerville, B.E. Persson A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America J Urol 180 2008 1986 1992
-
(2008)
J Urol
, vol.180
, pp. 1986-1992
-
-
Gittelman, M.1
Pommerville, P.J.2
Persson, B.E.3
-
14
-
-
50849110501
-
Degarelix: A novel gonadotrophin-releasing hormone (GnRH) blocker - Results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer
-
H. Van Poppel, B. Tombal, J.J. de la Rosette Degarelix: a novel gonadotrophin-releasing hormone (GnRH) blocker - results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer Eur Urol 54 2008 805 813
-
(2008)
Eur Urol
, vol.54
, pp. 805-813
-
-
Van Poppel, H.1
Tombal, B.2
De La Rosette, J.J.3
-
15
-
-
77949653652
-
Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics
-
B. Tombal, K. Miller, L. Boccon-Gibod Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics Eur Urol 57 2010 836 842
-
(2010)
Eur Urol
, vol.57
, pp. 836-842
-
-
Tombal, B.1
Miller, K.2
Boccon-Gibod, L.3
-
16
-
-
0028786511
-
Bicalutamide in the treatment of advanced prostatic carcinoma: A phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy
-
M.S. Soloway, P.F. Schellhammer, J.A. Smith Jr. Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy J Urol 154 6 1995 2110 2114
-
(1995)
J Urol
, vol.154
, Issue.6
, pp. 2110-2114
-
-
Soloway, M.S.1
Schellhammer, P.F.2
Smith, Jr.J.A.3
-
17
-
-
0028875365
-
Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial Zoladex Prostate Study Group
-
N.J. Vogelzang, G.W. Chodak, M.S. Soloway Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial Zoladex Prostate Study Group Urology 46 2 1995 220 226
-
(1995)
Urology
, vol.46
, Issue.2
, pp. 220-226
-
-
Vogelzang, N.J.1
Chodak, G.W.2
Soloway, M.S.3
-
18
-
-
77149159440
-
Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: Prognostic significance?
-
M. Perachino, V. Cavalli, F. Bravi Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 105 5 2010 648 651
-
(2010)
BJU Int
, vol.105
, Issue.5
, pp. 648-651
-
-
Perachino, M.1
Cavalli, V.2
Bravi, F.3
-
19
-
-
78549231887
-
Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer
-
M. Roach 3rd, K. Bae, C. Lawton Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 78 5 2010 1314 1322
-
(2010)
Int J Radiat Oncol Biol Phys
, vol.78
, Issue.5
, pp. 1314-1322
-
-
Roach III, M.1
Bae, K.2
Lawton, C.3
-
20
-
-
34547118594
-
The Importance of Testosterone Control in Prostate Cancer
-
DOI 10.1016/j.eursup.2007.06.002, PII S1569905607001728
-
B. Tombal The importance of testosterone control in prostate cancer Eur Urol Suppl 6 2007 834 839 (Pubitemid 47102240)
-
(2007)
European Urology, Supplements
, vol.6
, Issue.15
, pp. 834-839
-
-
Tombal, B.1
-
21
-
-
44549087997
-
What is new in hormone therapy for prostate cancer in 2007?
-
B. Tombal What is new in hormone therapy for prostate cancer in 2007? Eur Urol Suppl 7 2008 477 483
-
(2008)
Eur Urol Suppl
, vol.7
, pp. 477-483
-
-
Tombal, B.1
-
22
-
-
33646248080
-
Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer
-
R. Berges, U. Bello Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer Curr Med Res Opin 22 2006 649 655
-
(2006)
Curr Med Res Opin
, vol.22
, pp. 649-655
-
-
Berges, R.1
Bello, U.2
-
23
-
-
34548400276
-
Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation Therapy
-
DOI 10.1016/j.juro.2007.05.129, PII S0022534707014000
-
J. Morote, A. Orsola, J. Planas Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy J Urol 178 2007 1290 1295 (Pubitemid 47368393)
-
(2007)
Journal of Urology
, vol.178
, Issue.4
, pp. 1290-1295
-
-
Morote, J.1
Orsola, A.2
Planas, J.3
Trilla, E.4
Raventos, C.X.5
Cecchini, L.6
Catalan, R.7
-
24
-
-
0035516095
-
A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer
-
D. McLeod, N. Zinner, K. Tomera A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer Urology 58 2001 756 761
-
(2001)
Urology
, vol.58
, pp. 756-761
-
-
McLeod, D.1
Zinner, N.2
Tomera, K.3
-
25
-
-
0036128522
-
A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer
-
J. Trachtenberg, M. Gittleman, C. Steidle A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer J Urol 167 2002 1670 1674 (Pubitemid 34240698)
-
(2002)
Journal of Urology
, vol.167
, Issue.I4
, pp. 1670-1674
-
-
Trachtenberg, J.1
Gittleman, M.2
Steidle, C.3
Barzell, W.4
Friedel, W.5
Pessis, D.6
Fotheringham, N.7
Campion, M.8
Garnick, M.B.9
-
26
-
-
80051764006
-
An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer
-
L. Boccon-Gibod, E. Van der Meulen, B.E. Persson An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer Ther Adv Urol 3 3 2011 127 140
-
(2011)
Ther Adv Urol
, vol.3
, Issue.3
, pp. 127-140
-
-
Boccon-Gibod, L.1
Van Der Meulen, E.2
Persson, B.E.3
-
27
-
-
0023859321
-
Clinical utility of prostatic specific antigen and prostatic acid phosphatase serum levels in monitoring prostate cancer
-
J. Morote, A. Ruibal, J. Palou Clinical utility of prostatic specific antigen and prostatic acid phosphatase serum levels in monitoring prostate cancer Int J Biol Markers 3 1988 23 28
-
(1988)
Int J Biol Markers
, vol.3
, pp. 23-28
-
-
Morote, J.1
Ruibal, A.2
Palou, J.3
-
28
-
-
0024538468
-
Changes in prostate-specific markers under chronic gonadotrophin- releasing hormone analogue treatment of stage D prostatic cancer
-
DOI 10.1002/1097-0142(19890401)63:7<1287::AID-CNCR2820630710>3.0. CO;2-7
-
H. Matzkin, O. Lewyshon, D. Ayalon Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of state D prostatic cancer Cancer 63 1989 1287 1291 (Pubitemid 19084547)
-
(1989)
Cancer
, vol.63
, Issue.7
, pp. 1287-1291
-
-
Matzkin, H.1
Lewyshon, O.2
Ayalon, D.3
Braf, Z.4
-
29
-
-
0029077920
-
Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma
-
J.A. Storlie, J.C. Buckner, G.A. Wiseman Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma Cancer 76 1995 96 100
-
(1995)
Cancer
, vol.76
, pp. 96-100
-
-
Storlie, J.A.1
Buckner, J.C.2
Wiseman, G.A.3
-
30
-
-
0031832733
-
Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
-
D.C. Smith, R.L. Dunn, M.S. Strawderman Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer J Clin Oncol 16 1998 1835 1843 (Pubitemid 28234729)
-
(1998)
Journal of Clinical Oncology
, vol.16
, Issue.5
, pp. 1835-1843
-
-
Smith, D.C.1
Dunn, R.L.2
Strawderman, M.S.3
Pienta, K.J.4
|